Pfizer secures EC approval for Velsipity to treat active ulcerative colitis
The EC approval of Velsipity was supported by results from the Phase 3 ELEVATE UC registrational programme, which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Feb 24
The EC approval of Velsipity was supported by results from the Phase 3 ELEVATE UC registrational programme, which…
19 Feb 24
The FDA approval is based on data from the Phase 3 OUtMATCH study, which showed a high proportion…
19 Feb 24
The approval was based on the findings from the FLAURA2 trial in which Tagrisso with chemotherapy reduced the…
15 Feb 24
The effectiveness of iloprost in treating severe frostbite was determined by an open-label, controlled trial in which none…
13 Feb 24
The FDA approval was based on efficacy and safety findings from two multicentre, randomised, double-blind, parallel-group, placebo-controlled 12-week…
13 Feb 24
The EC approval was driven by the efficacy and safety data from the placebo-controlled MOXIe Part 2 study…
08 Feb 24
Eli Lilly alleged that some its products were being processed at sites affected by the deal as Catalent…
06 Feb 24
Myalepta is indicated as a replacement therapy as an adjunct to diet to treat the complications of leptin…
05 Feb 24
Genmab and Pfizer’s marketing authorisation application (MAA) for Tisotumab vedotin, an antibody-drug conjugate (ADC) intended for the treatment…
05 Feb 24
The approval was based on the positive outcomes of the ReSTORE Phase 3 clinical trial in which rezafungin…